File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Industry sponsored oncology clinical trials

TitleIndustry sponsored oncology clinical trials
Authors
Issue Date2009
PublisherClinical Trials Centre. The University of Hong Kong, Li Ka Shing Faculty of Medicine. The Journal's web site is located at http://www.clinicalresearchclinic.com/default.aspx
Citation
Clinical Trial Magnifier, 2009, v. 2 n. 8, p. 402-416 How to Cite?
AbstractThe US clinical trial register data was analysed to characterise industry and partially non-industry sponsored oncology clinical trials. The analysis found 2,248 trials with 45,882 study sites and 420,378 study subjects for industry-sponsored oncology phase I-IV trials on drugs and biologics. We previously reported that most industry-sponsored trials were in oncology, followed by CNS, cardiology, infectious diseases, endocrinology and respiratory diseases. We can now report that over the past two years the number of cancer trials and sites has increased proportionate by about twice as much as all other therapeutic areas combined. Oncology now accounts for 20.8% of all industry sponsored trials and 20.9% of all sites. Non-industry sponsored oncology trials account for 40.1% of all these, and 75.7% of sites. The total projected number of subjects to be recruited into industry sponsored trials – over 46 months up to July 2009 – is 4.1 million, compared with 1.8 million for non-industry sponsored trials. Prostate, breast, lung and colorectal-anal cancers have the highest incidence rate in the US, affecting between 72.0 and 50.6 per 100,000 population. They account for 54.6% of all cancer types and represent 49.4% of all industry sponsored oncology clinical trial subjects. Oncology trials are notably more global in nature than others. For instance, 45.8% of oncology phase III trial sites are global, compared with 32.2% for all other therapeutics areas. The corresponding subjects for recruitment are 37.7% and 28.2%, respectively. In conclusion, oncology has become the main focus of the industry in developing new medicinal products. This is because cancer is a leading cause of death and chronic in nature with a large market – the second largest by therapeutic area with positive year-by-year growth. At the same time, the industry faces strong competition to identify cancer trial subjects not just from its industrial competitors, but also from very popular investigator-initiated oncology trials. This explains why industry sponsored oncology trials are more globalised than other therapeutic area trials.
Persistent Identifierhttp://hdl.handle.net/10722/87597
ISSN

 

DC FieldValueLanguage
dc.contributor.authorKarlberg, JPEen_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorYau, HKCen_HK
dc.date.accessioned2010-09-06T09:31:54Z-
dc.date.available2010-09-06T09:31:54Z-
dc.date.issued2009en_HK
dc.identifier.citationClinical Trial Magnifier, 2009, v. 2 n. 8, p. 402-416en_HK
dc.identifier.issn2078-8185en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87597-
dc.description.abstractThe US clinical trial register data was analysed to characterise industry and partially non-industry sponsored oncology clinical trials. The analysis found 2,248 trials with 45,882 study sites and 420,378 study subjects for industry-sponsored oncology phase I-IV trials on drugs and biologics. We previously reported that most industry-sponsored trials were in oncology, followed by CNS, cardiology, infectious diseases, endocrinology and respiratory diseases. We can now report that over the past two years the number of cancer trials and sites has increased proportionate by about twice as much as all other therapeutic areas combined. Oncology now accounts for 20.8% of all industry sponsored trials and 20.9% of all sites. Non-industry sponsored oncology trials account for 40.1% of all these, and 75.7% of sites. The total projected number of subjects to be recruited into industry sponsored trials – over 46 months up to July 2009 – is 4.1 million, compared with 1.8 million for non-industry sponsored trials. Prostate, breast, lung and colorectal-anal cancers have the highest incidence rate in the US, affecting between 72.0 and 50.6 per 100,000 population. They account for 54.6% of all cancer types and represent 49.4% of all industry sponsored oncology clinical trial subjects. Oncology trials are notably more global in nature than others. For instance, 45.8% of oncology phase III trial sites are global, compared with 32.2% for all other therapeutics areas. The corresponding subjects for recruitment are 37.7% and 28.2%, respectively. In conclusion, oncology has become the main focus of the industry in developing new medicinal products. This is because cancer is a leading cause of death and chronic in nature with a large market – the second largest by therapeutic area with positive year-by-year growth. At the same time, the industry faces strong competition to identify cancer trial subjects not just from its industrial competitors, but also from very popular investigator-initiated oncology trials. This explains why industry sponsored oncology trials are more globalised than other therapeutic area trials.-
dc.languageengen_HK
dc.publisherClinical Trials Centre. The University of Hong Kong, Li Ka Shing Faculty of Medicine. The Journal's web site is located at http://www.clinicalresearchclinic.com/default.aspxen_HK
dc.relation.ispartofClinical Trial Magnifieren_HK
dc.titleIndustry sponsored oncology clinical trialsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=2078-8185&volume=2&issue=8&spage=402&epage=416&date=2009&atitle=Industry+sponsored+oncology+clinical+trialsen_HK
dc.identifier.emailKarlberg, JPE: jpekarl@hkucc.hku.hken_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros166164en_HK
dc.identifier.volume2-
dc.identifier.issue8-
dc.identifier.spage402-
dc.identifier.epage416-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats